ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH EVAN YU
Management of mCRPC using Sipuleucel-T

VIEW ALL mCRPC VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH JACOB BERCHUCK & MARY-ELLEN TAPLIN
Genetic Risk in Prostate Cancer

VIEW ALL PROSTATE CANCER VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH KARIM FIZAZI
ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life

VIEW ALL nmCRPC VIDEOS

EAU 2019 ANNUAL MEETING

EAU 2019 ANNUAL MEETING

INTERVIEW WITH THOMAS POWLES
Immunotherapy in the Peri-Operative Setting for Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

#AUA14 - Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: A propensity score matched analysis - Session Highlights

ORLANDO, FL USA (UroToday.com) - Renal cancer at its advanced stage is often associated with tumor thrombus that can either extend into the renal vein or the inferior vena cava. Shingo Hatakeyama presented his group’s assessment of surgical management of tumor thrombus and analysis of its benefit in patients with renal cell carcinoma.

auaThe authors identified 42 patients who had tumor thrombus in a renal vein and 43 patients who had tumor thrombus in the IVC. The authors reviewed factors that could potentially be prognostic in the treatment of these patients. To assess whether surgical treatment would benefit patients with thrombus in the major veins, the authors used propensity score matching to compare whether patients who had received surgical treatment had better overall survival than those who did not receive any therapy. After completing propensity score matching, patients who had undergone surgical treatment for their tumor thrombus had better survival than patients who had not received any surgical treatment.

The authors concluded that patients with surgical treatment for tumor thrombus might do better than patients not receiving surgery. The improved survival, however, needs to be evaluated in a larger sample, and prospectively. The authors did not discuss the reasons for which patients were not treated surgically. The results of this inquiry might increase the meaning of the potentially impactful results the authors observed in their retrospective study.

Presented by Shingo Hatakeyama, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Hirosaki, Japan

Written by Garen Abedi, MD, University of California (Irvine), and medical writer for UroToday.com

 

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe